InflaRx NV (STU:IF0)
€ 2.022 0 (0%) Market Cap: 141.14 Mil Enterprise Value: 84.15 Mil PE Ratio: 0 PB Ratio: 2.04 GF Score: 38/100

Q4 2023 InflaRx NV Earnings Call Transcript

Mar 21, 2024 / 12:00PM GMT
Release Date Price: €1.48 (-4.03%)
Jan Medina
InflaRx GmbH - Vice President, Head of Investor Relations

Good morning, everyone. Thank you for standing by and thank you for joining InflaRx's conference call to discuss the company's expected development plans for INF904, our orally available C5aR inhibitor with best-in-class potential. Presenting on today's call, we have Niels Riedemann, CEO and Founder; and Camilla Chong, Chief Medical Officer; with Renfeng Guo as CSO and founder; and Thomas Taapken, CFO available during the Q&A session.

During today's presentation, all participants will be in a listen only mode. Please note that today's call is being recorded. The presentation will be followed by a Q&A session where you may ask written or audio questions and please note that you can ask questions only online. I would now like to turn the call over to Dr. Niels Riedemann, CEO and Founder of InflaRx. Niels, please go ahead.

Niels Riedemann
InflaRx GmbH - Chief Executive Officer and Founder

Yes. Thank you so much, Jan. We're really excited to have everyone on the call today to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot